Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Other hematologic neoplasm 1Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 10Myelodysplastic Syndromes 6Leukemia, Myelomonocytic, Chronic 3Neoplasms 1Myeloproliferative Disorders 1Glioma 1Cholangiocarcinoma 1

Interventions

trametinib 3dabrafenib 3Paclitaxel 2Nivolumab 2ulixertinib 1trastuzumab biosimilar HLX02 1sargramostim 1sapanisertib 1romidepsin 1ripretinib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1olutasidenib 1liposomal doxorubicin 1larotrectinib 1ipatasertib 1erdafitinib 1entrectinib 1entinostat 1defactinib 1copanlisib 1cobimetinib 1carboxyamido-triazole 1capmatinib 1capivasertib 1binimetinib 1bempegaldesleukin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × olutasidenib × Other hematologic neoplasm × Clear all
NCT07486713 2026-03-20

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡